Treatment of Women After Postpartum Haemorrhage
A, Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Standard Medical Care in Women After Postpartum Haemorrhage
The primary purpose of this study is to compare the efficacy of IV high single dose infusion of iron isomaltoside 1000 to standard medical care in women with PPH evaluated as physical fatigue.
A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
Inclusion Criteria: Women with PPH ≥ 700 and ≤ 1000 mL or PPH > 1000 mL and Hb > 6.5 g/dL (4.0 mmol/L) measured > 12 hours after delivery Willingness to participate and signed the informed consent form Exclusion Criteria: Women aged < 18 years Multiple births Peripartum RBC transfusion Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis) Known hypersensitivity to parenteral iron or any excipients in the investigational drug products Women with a history of active asthma within the last 5 years or a history of multiple allergies Known decompensated liver cirrhosis and active hepatitis Women with HELLP (Haemolysis Elevated Liver enzymes Low Platelet count) syndrome (defined according to "Dansk Selskab for Obstetrik og Gynækologi guidelines") Active acute infection assessed by clinical judgement Rheumatoid arthritis with symptoms or signs of active joint inflammation History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia (known haematologic disorder other than iron deficiency) Not able to read, speak and understand the Danish language Participation in any other clinical study where the study drug has not passed 5 half-lives prior to the baseline Any other medical condition that, in the opinion of the Investigator, may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from being in the study. For example, a malignancy, uncontrolled hypertension, unstable ischaemic heart disease or uncontrolled diabetes mellitus